

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Monoclonal antibody Sarilumab compared to Standard treatment be used for COVID-19 patients?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Monoclonal antibody Sarilumab	Standard treatment	Relative (95% CI)	Absolute (95% CI)	

All-cause mortality

3 ^{1,2,3}	randomised trials	not serious	not serious	not serious	not serious	none	73/401 (18.2%)	173/576 (30.0%)	RR 0.85 (0.59 to 1.22)	45 fewer per 1.000 (from 123 fewer to 66 more)	⊕⊕⊕⊕ HIGH
--------------------	-------------------	-------------	-------------	-------------	-------------	------	----------------	-----------------	----------------------------------	--	--------------

Number of patients with serious adverse events

3 ^{1,2,3}	randomised trials	not serious	not serious	not serious	not serious	none	135/221 (23.1%)	31/486 (6.4%)	RR 1.20 (0.77 to 1.87)	13 more per 1.000 (from 15 fewer to 55 more)	⊕⊕⊕⊕ HIGH
--------------------	-------------------	-------------	-------------	-------------	-------------	------	-----------------	---------------	----------------------------------	--	--------------

Duration of hospitalization in intensive care

1 ¹	randomised trials	serious ^a	not serious	not serious	not serious	none	HR: 1.64 (IC95% (1.21 to 2.45))			⊕⊕⊕○ MODERATE
----------------	-------------------	----------------------	-------------	-------------	-------------	------	---------------------------------	--	--	------------------

Length of stay in hospital

1 ¹	randomised trials	serious ^a	not serious	not serious	not serious	none	HR: 1.60 [IC95% (1.17 to 2.19)]			⊕⊕⊕○ MODERATE
----------------	-------------------	----------------------	-------------	-------------	-------------	------	---------------------------------	--	--	------------------

Number of patients with any adverse events

1 ²	randomised trials	not serious	not serious	not serious	not serious	none	121/173 (69.9%)	55/84 (65.5%)	RR 1.07 (0.89 to 1.28)	46 more per 1.000 (from 72 fewer to 183 more)	⊕⊕⊕⊕ HIGH
----------------	-------------------	-------------	-------------	-------------	-------------	------	-----------------	---------------	----------------------------------	---	--------------

Explanations

- a. Downgraded of one level for high risk of performance bias in one study and unclear risk of attrition and reporting bias in the other study

References

1. Gordon AC, Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, et al The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19 – Preliminary report. medRxiv. 2021:2021.01.07.21249390.
2. Lescure F-X, Honda H, Fowler RA, Lazar JS, Shi G, Wung P, et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. medRxiv. 2021:2021.02.01.21250769.
3. Sivapalasingam S, Lederer DJ, Bhore R, Hajizadeh N, Criner G, Hossain R, et al. A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19. medRxiv. DOI: 10.1101/2021.05.13.21256973